Your session is about to expire
← Back to Search
S-531011 + Pembrolizumab for Cancer (aCCeleR8-001 Trial)
aCCeleR8-001 Trial Summary
This trialtests a drug to see if it is safe and effective against cancer.
aCCeleR8-001 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowaCCeleR8-001 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.aCCeleR8-001 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant, breastfeeding, or trying to become pregnant.My cancer type is one of those specifically selected for this trial's Part C.I have one of the specified types of cancer (e.g., melanoma, lung, breast).I have brain metastasis that is not under control.I am fully active or restricted in physically strenuous activity but can do light work.I stopped a specific cancer treatment due to severe side effects.My advanced cancer has no standard treatment options left, or I can't or won't use them.I am willing to provide fresh tumor samples before and during treatment.I have had a transplant of tissue or an organ from another person.I have not had major surgery in the last 28 days.I haven't received blood growth factors or transfusions in the last 14 days.I haven't had extensive radiotherapy in the last 28 days or any for palliation in the last 14 days, nor have I had radiation pneumonitis.I am 18 years old or older and can legally consent.I agree to let the study use my stored cancer tissue samples.I have recovered from past treatment side effects, except for hair loss and nerve issues.I have or had lung disease or inflammation treated with steroids.I haven't taken any cancer drugs in the last 28 days or 5 half-lives, whichever is shorter.I have another cancer that is getting worse or was treated in the last 3 years.My cancer type is one of those selected by the study after its first phase.My cancer type is one of those selected by the study after initial dose findings.My cancer type is one of those selected by the study after its first phase.I haven't had a serious infection or been hospitalized for one in the last 4 weeks.I do not have severe heart disease.My blood and organ tests show normal function.I have not received a live vaccine in the last 30 days.I have an autoimmune disease requiring daily steroids or immunosuppressants.I have never been treated with anti-CCR8 antibody.I am willing to provide tumor samples before and during treatment.I am at least 18 years old, or 20 if I am in Japan.
- Group 1: Part C: S-531011 + pembrolizumab
- Group 2: Part A-2: S-531011 + pembrolizumab
- Group 3: Part A-1: S-531011 Monotherapy
- Group 4: Part B: S-531011 Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any unfilled slots for enrolment in this clinical trial?
"Affirmative. According to clinicaltrials.gov, the trial was first initiated on May 30th 2022 and has since been updated as recently as October 6th of this year. The study is currently recruiting a total of 274 patients from 3 different sites."
To what medical condition is Part A-1: S-531011 Monotherapy most often applied?
"Part A-1: S-531011 Monotherapy is recommended for individuals dealing with malignant neoplasms, unresectable melanoma, or microsatellite instability high."
Could you provide a chronology of prior experiments conducted concerning Part A-1: S-531011 Monotherapy?
"Part A-1: S-531011 Monotherapy was first administered in 2010 at City of Hope. Out of the 251 trials that have taken place, 961 are still recruiting participants with a significant proportion located in Los Angeles, California."
How many humans are taking part in this medical test?
"This research project necessitates the recruitment of 274 suitable participants. Potential volunteers can sign up at either Angeles Clinic and Research Center in Los Angeles, or Henry Ford Health Centre in Michigan."
Share this study with friends
Copy Link
Messenger